SMTI
Price
$22.00
Change
+$0.94 (+4.46%)
Updated
Jan 30 closing price
Capitalization
196.58M
59 days until earnings call
Intraday BUY SELL Signals
TRUMY
Price
$13.07
Change
+$0.08 (+0.62%)
Updated
Jan 30 closing price
Capitalization
19.43B
12 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

SMTI vs TRUMY

Header iconSMTI vs TRUMY Comparison
Open Charts SMTI vs TRUMYBanner chart's image
Sanara MedTech
Price$22.00
Change+$0.94 (+4.46%)
Volume$77.82K
Capitalization196.58M
Terumo
Price$13.07
Change+$0.08 (+0.62%)
Volume$411.39K
Capitalization19.43B
SMTI vs TRUMY Comparison Chart in %
SMTI
Daily Signal:
Gain/Loss:
TRUMY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
SMTI vs. TRUMY commentary
Feb 01, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SMTI is a Hold and TRUMY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 01, 2026
Stock price -- (SMTI: $22.00 vs. TRUMY: $13.07)
Brand notoriety: SMTI and TRUMY are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: SMTI: 163% vs. TRUMY: 112%
Market capitalization -- SMTI: $196.58M vs. TRUMY: $19.43B
SMTI [@Pharmaceuticals: Other] is valued at $196.58M. TRUMY’s [@Pharmaceuticals: Other] market capitalization is $19.43B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $178.74B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $11.52B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SMTI’s FA Score shows that 0 FA rating(s) are green whileTRUMY’s FA Score has 2 green FA rating(s).

  • SMTI’s FA Score: 0 green, 5 red.
  • TRUMY’s FA Score: 2 green, 3 red.
According to our system of comparison, TRUMY is a better buy in the long-term than SMTI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SMTI’s TA Score shows that 2 TA indicator(s) are bullish while TRUMY’s TA Score has 4 bullish TA indicator(s).

  • SMTI’s TA Score: 2 bullish, 6 bearish.
  • TRUMY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, TRUMY is a better buy in the short-term than SMTI.

Price Growth

SMTI (@Pharmaceuticals: Other) experienced а +1.15% price change this week, while TRUMY (@Pharmaceuticals: Other) price change was -4.39% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.17%. For the same industry, the average monthly price growth was +1.50%, and the average quarterly price growth was +26.40%.

Reported Earning Dates

SMTI is expected to report earnings on Apr 01, 2026.

TRUMY is expected to report earnings on Feb 13, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (-2.17% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TRUMY($19.4B) has a higher market cap than SMTI($197M). SMTI YTD gains are higher at: -5.782 vs. TRUMY (-9.862). TRUMY has higher annual earnings (EBITDA): 260B vs. SMTI (4.78M). TRUMY has more cash in the bank: 217B vs. SMTI (14.9M). SMTI has less debt than TRUMY: SMTI (47.4M) vs TRUMY (160B). TRUMY has higher revenues than SMTI: TRUMY (1.06T) vs SMTI (102M).
SMTITRUMYSMTI / TRUMY
Capitalization197M19.4B1%
EBITDA4.78M260B0%
Gain YTD-5.782-9.86259%
P/E RatioN/A22.60-
Revenue102M1.06T0%
Total Cash14.9M217B0%
Total Debt47.4M160B0%
FUNDAMENTALS RATINGS
SMTI vs TRUMY: Fundamental Ratings
SMTI
TRUMY
OUTLOOK RATING
1..100
5450
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
32
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9919
PRICE GROWTH RATING
1..100
8283
P/E GROWTH RATING
1..100
10091
SEASONALITY SCORE
1..100
5019

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRUMY's Valuation (32) in the null industry is somewhat better than the same rating for SMTI (88). This means that TRUMY’s stock grew somewhat faster than SMTI’s over the last 12 months.

TRUMY's Profit vs Risk Rating (100) in the null industry is in the same range as SMTI (100). This means that TRUMY’s stock grew similarly to SMTI’s over the last 12 months.

TRUMY's SMR Rating (19) in the null industry is significantly better than the same rating for SMTI (99). This means that TRUMY’s stock grew significantly faster than SMTI’s over the last 12 months.

SMTI's Price Growth Rating (82) in the null industry is in the same range as TRUMY (83). This means that SMTI’s stock grew similarly to TRUMY’s over the last 12 months.

TRUMY's P/E Growth Rating (91) in the null industry is in the same range as SMTI (100). This means that TRUMY’s stock grew similarly to SMTI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SMTITRUMY
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
62%
Momentum
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
76%
MACD
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
61%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
69%
Advances
ODDS (%)
N/A
Bullish Trend 11 days ago
66%
Declines
ODDS (%)
Bearish Trend 6 days ago
80%
Bearish Trend 4 days ago
68%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
71%
Aroon
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 3 days ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
SMTI
Daily Signal:
Gain/Loss:
TRUMY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VKQ9.770.01
+0.10%
Invesco Municipal Trust
QBIG38.030.02
+0.06%
Invesco Top QQQ ETF
PJFM64.46N/A
N/A
PGIM Jennison Focused Mid-Cap ETF
CGO12.32-0.07
-0.56%
Calamos Global Total Return Fund
IEUR74.23-0.68
-0.91%
iShares Core MSCI Europe ETF

TRUMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRUMY has been loosely correlated with HOCPY. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if TRUMY jumps, then HOCPY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRUMY
1D Price
Change %
TRUMY100%
+0.62%
HOCPY - TRUMY
51%
Loosely correlated
+0.86%
SSMXY - TRUMY
45%
Loosely correlated
+1.18%
SMTI - TRUMY
43%
Loosely correlated
+4.46%
OLYMY - TRUMY
40%
Loosely correlated
-0.50%
AZTA - TRUMY
39%
Loosely correlated
-0.31%
More